Alpha 2.0
Login Register
» Authors » C Chabannon

C Chabannon

Explore the profile of C Chabannon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 132
Citations 857
Followers 0
Related Specialties
General Surgery
Oncology
Hematology
Top 10 Co-Authors
D Blaise
C Faucher
D Maraninchi
R Bouabdallah
N Vey
P Viens
S Furst
M Mohty
G Novakovitch
R Crocchiolo
Published In
Bone Marrow Transplant
Leukemia
Hematol Cell Ther
Blood
Ann Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party
Daenen L, van der Wagen L, Bonneville E, Lopez-Corral L, Bukauskas A, Bornhauser M, et al.
Bone Marrow Transplant . 2025 Feb; PMID: 39979522
Acute graft-versus-host disease (aGvHD) remains a significant complication of allogeneic hematopoietic cell transplantation, with 40% of patients failing to respond to high-dose steroids. Ruxolitinib has become the standard treatment for...
2.
Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart J, et al.
Ann Oncol . 2023 Dec; 35(4):404-406. PMID: 38145867
No abstract available.
3.
Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working...
Worel N, Ljungman P, Verheggen I, Hoogenboom J, Knelange N, Eikema D, et al.
Bone Marrow Transplant . 2023 Sep; 58(12):1348-1356. PMID: 37673982
The COVID-19 pandemic has had a significant impact on medical practices, including the delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant centers have made changes to their procedures,...
4.
Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party
de Witte M, Mooyaart J, Hoogenboom J, Chabannon C, Malard F, Ruggeri A, et al.
Bone Marrow Transplant . 2023 Mar; 58(6):719-722. PMID: 36934148
No abstract available.
5.
The first steps towards a diverse and inclusive EBMT: a position paper
Montoto S, Snowden J, Chabannon C, Corbacioglu S, de la Camara R, Dolstra H, et al.
Bone Marrow Transplant . 2022 Feb; 57(3):343-346. PMID: 35121807
No abstract available.
6.
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European...
Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C, et al.
Ann Oncol . 2021 Dec; 33(3):259-275. PMID: 34923107
Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle...
7.
Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic
Mfarrej B, Lemarie C, Granata A, Pagliardini T, Malenfant C, Lignee P, et al.
Bone Marrow Transplant . 2021 Apr; 56(8):2013-2015. PMID: 33846562
No abstract available.
8.
Development of adaptive immune effector therapies in solid tumors
Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, et al.
Ann Oncol . 2019 Aug; 30(11):1740-1750. PMID: 31435646
State-of-the-art treatment strategies have drastically ameliorated the outcome of patients affected by cancer. However, resistant and recurrent solid tumors are generally nonresponsive to conventional therapies. A central factor in the...
9.
[CAR-T cells: Lymphocytes that express a chimeric antigen receptor]
Chabannon C, Bouabdallah R, Furst S, Granata A, Saillard C, Vey N, et al.
Rev Med Interne . 2019 Jan; 40(8):545-552. PMID: 30686549
CAR-T cells are genetically modified human lymphocytes and gene therapy medicinal products. They are developed to treat cancers that express a membrane antigen targeted by the CAR. The FDA approved...
10.
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT
Castagna L, Boubdallah R, Furst S, Coso D, El Cheikh J, Faucher C, et al.
Bone Marrow Transplant . 2018 Feb; 53(2):234. PMID: 29410535
This corrects the article DOI: 10.1038/bmt.2012.225.